If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
King Nur-el with his team of advisors, the high shaman Polano, Talis his aide and the doctor, discuss the nature of the coronavirus family and the epidemic in detail to create a plan to defeat the pandemic at the gates of the kingdom. "Halting the Coronavirus at the Gates of Pamona" a book published through Kotarim International Publishing in November 2021.
First proposed in 1972 by Meldner, such a reaction might enable the production of macroscopic quantities of superheavy elements within the island of stability; the role of fission in intermediate superheavy nuclides is highly uncertain, and may strongly influence the yield of such a reaction.
These multidisciplinary teams leverage the Barshop Institute's nationally recognized aging research programs—including the Nathan Shock Center of Excellence in the Basic Biology of Aging, the Claude D. Pepper Older Americans Independence Center, the Center for Alzheimer's Disease and Related Dementias Population Aging and Social Studies (CAPAS), and the Interventions Testing Program—to rapidly translate mechanistic discoveries into human studies. This integrated research environment enables investigators to evaluate interventions targeting the fundamental biological mechanisms of aging rather than focusing solely on individual diseases, reflecting the principles of geroscience that underpin the Institute's research mission. A landmark addition to the Institute's clinical research portfolio is the Validation and Intervention Testing for Aging, Longevity and Healthspan (VITAL-H) clinical trial, supported by a contract of up to $38 million from the Advanced Research Projects Agency for Health (ARPA-H) through its Proactive Solutions for Prolonging Resilience (PROSPR) program. As the coordinating center for this first-of-its-kind national healthspan clinical trial, the Barshop Institute is leading an unprecedented effort to determine whether FDA-approved medications can slow the biological processes of aging and preserve health and functional capacity before the onset of chronic disease.
1848: American astronomer Maria Mitchell became the first woman elected to the American Academy of Arts and Sciences; she had discovered a new comet the year before. 1848–1849: English scientist Mary Anne Whitby, a pioneer in western silkworm cultivation, collaborated with Charles Darwin in researching the hereditary qualities of silkworms. 1850: The American Association for the Advancement of Sciences accepted its first women members: astronomer Maria Mitchell, entomologist Margaretta Morris, and science educator Almira Hart Lincoln Phelps.
(a) Description. Evaporated milk is the liquid food obtained by partial removal of water only from milk. It contains not less than 6.5 percent by weight of milk fat, not less than 16.5 percent by weight of milk solids not fat, and not less than 23 percent by weight of total milk solids. Evaporated milk contains added vitamin D as prescribed by paragraph (b) of this section. It is homogenized. It is sealed in a container and so processed by heat, either before or after sealing, as to prevent spoilage. ...
Sources: en.wikipedia.org
Boli or bole is the term used for roasted plantain in Nigeria. The plantain is usually grilled and served with roasted fish, ground peanuts and a hot palm oil sauce. It is a dish native to the Yoruba people of Western Nigeria. It is popular among the working class as an inexpensive midday meal. Plantain is popular in West and Central Africa, especially Cameroon, Democratic Republic of Congo, Bénin, Ghana and Nigeria; when ripe plantain is fried, it is generally called dodo ("dough-dough"). The ripe plantain is usually sliced diagonally for a large oval shape, then fried in oil to a golden brown color. The diagonal slice maximizes the surface area, allowing the plantain to cook evenly. Fried plantain can be eaten as such, or served with stew or sauce. In Ikire, a town in Osun State in southwestern Nigeria, there is a special way of preparing fried plantain known as Dodo Ikire. This variation of Dodo (Fried Plantain) is made from overripe plantain, chopped into small pieces, sprinkled with chili pepper and then fried in boiling point palm oil until the pieces turn blackish. The fried plantains are then stuffed carefully into a plastic funnel and then pressed using a wooden pestle to compress and acquire a conical shape when removed. In Ghana, the dish is called kelewele and can be found as a snack sold by street vendors. Though sweeter and spicier variations exist, kelewele is often flavored with nutmeg, chili powder, ginger and salt.
Pneumatic non-return valves provide the ability to lock the valve, hence preventing flow in either direction. This may be used if for example a site with hazardous materials should be protected from flood water, however it is also important that the materials can't leak, for example during transfer between vessels.
== Early life and education == Robert S. Swanson was born in Brooklyn, New York, in 1947 to Arthur J. Swanson and Arline Baker Swanson. Arthur Swanson was an airplane electrical maintenance crew leader, and worked in shifts. According to Swanson, he was taught from an early age that his generation would do better than the last generation of his family. It was because of this that his family wanted him to be the first to obtain a college degree. His family was particularly interested in the Massachusetts Institute of Technology (MIT). Much to his family's pride, Swanson was accepted into MIT in 1965. Even though he was majoring in chemistry, he realized later during his undergraduate education that he preferred working with people, rather than in research. What follows is an excerpt from a 1996 interview that describes how he came to this realization: "At the end of my junior year, I... got a summer job working for a chemical company... One of the things I discovered was that I enjoyed people more than things. So I said, 'Gee, this probably isn't going to be what I'd want to do all my life,'". As a result, Swanson petitioned MIT to be able to take the first year's courses at the Alfred P. Sloan School of Management for a master's degree, and they allowed him to do so. Thanks to the graduate courses he took, he realized that he was particularly interested in two things: organizational development, and the commercialization of innovative ideas. He graduated from MIT in 1970, with an undergraduate degree in chemistry and a Master of Science degree in management.
Oclacitinib, sold under the brand name Apoquel among others, is a veterinary medication used in the control of atopic dermatitis and pruritus from allergic dermatitis in dogs at least 12 months of age. Chemically, it is a synthetic cyclohexylamino-pyrrolopyrimidine Janus kinase inhibitor (JAK inhibitor) that is relatively selective for JAK1. It inhibits signal transduction when the JAK is activated and thereby helps downregulate expression of inflammatory cytokine. Oclacitinib was approved for use in the United States in 2013 and in the European Union in 2023. A flavored chewable form was approved for use in the United States in 2023.
The three substrates of this enzyme are saccharopine, oxidised nicotinamide adenine dinucleotide phosphate (NADP+), and water. Its products are L-glutamic acid, L-allysine, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is N6-(L-1,3-dicarboxypropyl)-L-lysine:NADP+ oxidoreductase (L-glutamate-forming). Other names in common use include saccharopine (nicotinamide adenine dinucleotide phosphate,, glutamate-forming) dehydrogenase, aminoadipic semialdehyde-glutamic reductase, aminoadipate semialdehyde-glutamate reductase, aminoadipic semialdehyde-glutamate reductase, epsilon-N-(L-glutaryl-2)-L-lysine:NAD+(P) oxidoreductase, (L-2-aminoadipate-semialdehyde forming), saccharopine reductase, 6-N-(L-1,3-dicarboxypropyl)-L-lysine:NADP+ oxidoreductase, and (L-glutamate-forming). This enzyme participates in lysine biosynthesis and lysine degradation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.